{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.29","upperLimit":"1.00","value":"1.0"},{"groupId":"OG001","lowerLimit":"0.29","upperLimit":"0.96","value":"0.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"After cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.29","upperLimit":"1.00","value":"1.0"},{"groupId":"OG001","lowerLimit":"0.29","upperLimit":"1.00","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"After cycle 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"The overall response rate of up to 6 cycles of VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide) in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) will be reported along with a 95% confidence interval. Complete response (CR) + Partial response (PR) was measured by the Lugano criteria. Complete response is disappearance of all detectable evidence of disease and disease-related symptoms. Partial response is a ≥50% decrease in the sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cohort 1, Arm 1: Participants with primary diffuse large B-cell lymphoma of the central nervous system (CNS) primary central nervous system lymphoma (PCNSL) or secondary CNS lymphoma (SCNSL).\n\nExperimental - Nivolumab on Day 1 with lenalidomide (days 1-14) for a 21-day cycle. Following Window, VIPOR-Nivo (venetoclax, ibrutinib, prednisone, Obinutuzumab, lenalidomide, and nivolumab) in 21-day cycles for up to 6 cycles.","id":"OG000","title":"Lenalidomide+Nivolumab Followed by Venetoclax, Ibrutinib,Prednisone, Obinutuzumab, Lenalidomide-Nivo"},{"description":"Participants with primary diffuse large B-cell lymphoma of the central nervous system (CNS) primary central nervous system lymphoma (PCNSL) or secondary CNS lymphoma (SCNSL). VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide) in 21-day cycles for up to 6 cycles.","id":"OG001","title":"Cohort 1, Arm 2: Experimental- VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide)"}],"paramType":"NUMBER","populationDescription":"3/4 participants are analyzed in Arm 1 and 7/10 are analyzed in Arm 2 \"after cycle 3\" because 1 patient in Arm 1 and 3 patients in Arm 2 did not complete 3 cycles of treatment and stopped earlier.\n\n3/4 participants are analyzed in Arm 1 and 3/10 are analyzed in Arm 2 \"after cycle 6\" because 1 patient in Arm 1 and 7 patients in Arm 2 did not complete 6 cycles of treatment and stopped earlier.","reportingStatus":"POSTED","timeFrame":"After cycles 3 and 6","title":"Proportion of Participants Overall Response Rate (Complete Response + Partial Response) to VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}